Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.

Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, Colombo M, Emionite L, Sangaletti S, Gulino A, Reverberi D, Massara R, Boccardo S, de Totero D, Salvi S, Cilli M, Pellicanò M, Manzoni M, Fabris S, Airoldi I, Valdora F, Ferrini S, Gentile M, Vigna E, Bossio S, De Stefano L, Palummo A, Iaquinta G, Cardillo M, Zupo S, Cerruti G, Ibatici A, Neri A, Fais F, Ferrarini M, Morabito F.

Sci Transl Med. 2018 Feb 14;10(428). pii: eaal1571. doi: 10.1126/scitranslmed.aal1571.

PMID:
29444977
2.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

3.

Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Bertaina A, Zorzoli A, Petretto A, Barbarito G, Inglese E, Merli P, Lavarello C, Brescia LP, De Angelis B, Tripodi G, Moretta L, Locatelli F, Airoldi I.

Oncoimmunology. 2016 Sep 27;6(2):e1216291. doi: 10.1080/2162402X.2016.1216291. eCollection 2017.

4.

Interleukin-30 Promotes Breast Cancer Growth and Progression.

Airoldi I, Cocco C, Sorrentino C, Angelucci D, Di Meo S, Manzoli L, Esposito S, Ribatti D, Bertolotto M, Iezzi L, Natoli C, Di Carlo E.

Cancer Res. 2016 Nov 1;76(21):6218-6229. Epub 2016 Aug 22.

5.

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20.

PMID:
27311934
6.

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.

Blood. 2016 Aug 4;128(5):667-79. doi: 10.1182/blood-2016-01-690743. Epub 2016 Jun 6.

7.

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N.

Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. No abstract available.

8.

IL-27 induces the expression of IDO and PD-L1 in human cancer cells.

Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M, Ferrini S.

Oncotarget. 2015 Dec 22;6(41):43267-80. doi: 10.18632/oncotarget.6530.

9.

IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma.

Prigione I, Covone AE, Giacopelli F, Bocca P, Risso M, Tripodi G, Pistorio A, Sozzi G, Airoldi I, Ravazzolo R, Pistoia V.

Immunobiology. 2016 Feb;221(2):291-9. doi: 10.1016/j.imbio.2015.10.006. Epub 2015 Oct 29.

PMID:
26547104
10.

SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis.

Russo MV, Esposito S, Tupone MG, Manzoli L, Airoldi I, Pompa P, Cindolo L, Schips L, Sorrentino C, Di Carlo E.

Oncotarget. 2016 Mar 15;7(11):12372-85. doi: 10.18632/oncotarget.6029.

11.

SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.

Esposito S, Russo MV, Airoldi I, Tupone MG, Sorrentino C, Barbarito G, Di Meo S, Di Carlo E.

Oncotarget. 2015 Jul 10;6(19):17121-34.

12.

Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer.

Airoldi I, Tupone MG, Esposito S, Russo MV, Barbarito G, Cipollone G, Di Carlo E.

Oncotarget. 2015 Feb 28;6(6):3694-708.

13.

γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes.

Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, Meazza R, Loiacono F, Lucarelli B, Bernardo ME, Barbarito G, Pende D, Moretta A, Pistoia V, Moretta L, Locatelli F.

Blood. 2015 Apr 9;125(15):2349-58. doi: 10.1182/blood-2014-09-599423. Epub 2015 Jan 22. Erratum in: Blood. 2016 Mar 24;127(12):1620.

14.

IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-γ release by autologous NK cells.

Morandi F, Airoldi I, Pistoia V.

J Immunol Res. 2014;2014:938561. doi: 10.1155/2014/938561. Epub 2014 Mar 10.

15.

The antitumor potential of Interleukin-27 in prostate cancer.

Di Carlo E, Sorrentino C, Zorzoli A, Di Meo S, Tupone MG, Ognio E, Mincione G, Airoldi I.

Oncotarget. 2014 Nov 15;5(21):10332-41.

16.

IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation.

Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I.

J Immunol. 2014 Mar 15;192(6):2634-42. doi: 10.4049/jimmunol.1302656. Epub 2014 Feb 19.

17.

Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage.

Di Meo S, Airoldi I, Sorrentino C, Zorzoli A, Esposito S, Di Carlo E.

Clin Cancer Res. 2014 Feb 1;20(3):585-94. doi: 10.1158/1078-0432.CCR-13-2240. Epub 2013 Nov 25.

18.

The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.

Carbotti G, Barisione G, Orengo AM, Brizzolara A, Airoldi I, Bagnoli M, Pinciroli P, Mezzanzanica D, Centurioni MG, Fabbi M, Ferrini S.

Clin Cancer Res. 2013 Sep 1;19(17):4611-20. doi: 10.1158/1078-0432.CCR-13-0568. Epub 2013 Jul 19.

19.

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2013 Aug;27(8):1697-706. doi: 10.1038/leu.2013.24. Epub 2013 Jan 24.

PMID:
23344526
20.

Graft-versus-host disease is ameliorated by blocking of IL-21 signaling.

Cocco C, Airoldi I.

Immunotherapy. 2012 Jul;4(7):669-70. No abstract available.

PMID:
23019745
21.

IL-22 as key factor of thymic regeneration.

Cocco C, Airoldi I.

Immunotherapy. 2012 Jul;4(7):668. No abstract available.

PMID:
23019744
22.

Tumor-associated macrophages: from cancer supporters to tumoricidal effectors.

Cocco C, Airoldi I.

Immunotherapy. 2012 Jul;4(7):667-8. doi: 10.2217/imt.12.56. No abstract available.

PMID:
22853751
23.

Human TCRγδ+ T cells represent a novel target for IL-27 activity.

Morandi F, Prigione I, Airoldi I.

Eur J Immunol. 2012 Jun;42(6):1547-52. doi: 10.1002/eji.201142241.

24.

Targeting acute myeloid leukemia cells with cytokines.

Ferretti E, Cocco C, Airoldi I, Pistoia V.

J Leukoc Biol. 2012 Sep;92(3):567-75. doi: 10.1189/jlb.0112036. Epub 2012 May 16. Review.

PMID:
22591693
25.

Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.

Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I.

Clin Cancer Res. 2012 Mar 15;18(6):1630-40. doi: 10.1158/1078-0432.CCR-11-2432. Epub 2012 Mar 1.

26.

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S.

PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.

27.

Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo.

Cocco C, Di Carlo E, Zupo S, Canale S, Zorzoli A, Ribatti D, Morandi F, Ognio E, Airoldi I.

Leukemia. 2012 Jun;26(6):1365-74. doi: 10.1038/leu.2011.363. Epub 2011 Dec 23.

PMID:
22193967
28.

Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia.

Cocco C, Pistoia V, Airoldi I.

Crit Rev Oncol Hematol. 2012 Sep;83(3):310-8. doi: 10.1016/j.critrevonc.2011.11.006. Epub 2011 Dec 15. Review.

PMID:
22177566
29.

Cytokines as anti-angiogenic agents in haematological malignancies.

Cocco C, Ferretti E, Airoldi I, Pistoia V.

Curr Cancer Drug Targets. 2011 Nov;11(9):997-1004. Review.

PMID:
21933108
30.

Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells.

Giuliani N, Airoldi I.

Clin Cancer Res. 2011 Nov 15;17(22):6963-70. doi: 10.1158/1078-0432.CCR-11-1724. Epub 2011 Aug 31. Review.

31.

Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.

Ferretti E, Montagna D, Di Carlo E, Cocco C, Ribatti D, Ognio E, Sorrentino C, Lisini D, Bertaina A, Locatelli F, Pistoia V, Airoldi I.

Leukemia. 2012 Feb;26(2):225-35. doi: 10.1038/leu.2011.213. Epub 2011 Aug 16.

PMID:
21844875
32.

Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia.

Cocco C, Airoldi I.

Cytokine Growth Factor Rev. 2011 Jun;22(3):149-56. doi: 10.1016/j.cytogfr.2011.05.003. Epub 2011 Jul 20. Review.

PMID:
21764355
33.

Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors.

Airoldi I, Ribatti D.

J Leukoc Biol. 2011 Nov;90(5):875-82. doi: 10.1189/jlb.0511237. Epub 2011 Jul 12. Review.

PMID:
21750124
34.

Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model.

Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, Ognio E, Sorrentino C, Ribatti D, Zorzoli A, Basso G, Dufour C, Airoldi I.

Leukemia. 2011 Dec;25(12):1815-24. doi: 10.1038/leu.2011.158. Epub 2011 Jun 24.

PMID:
21701492
35.

Interleukin-27 and interleukin-23 modulate human plasmacell functions.

Cocco C, Morandi F, Airoldi I.

J Leukoc Biol. 2011 May;89(5):729-34. doi: 10.1189/jlb.1210660. Epub 2011 Feb 17.

PMID:
21330353
36.

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N.

Leukemia. 2011 Mar;25(3):527-37. doi: 10.1038/leu.2010.270. Epub 2010 Nov 23.

37.

Direct inhibition of human acute myeloid leukemia cell growth by IL-12.

Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I.

Immunol Lett. 2010 Oct 30;133(2):99-105. doi: 10.1016/j.imlet.2010.08.002. Epub 2010 Aug 10.

PMID:
20705102
38.

Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells.

Cocco C, Canale S, Frasson C, Di Carlo E, Ognio E, Ribatti D, Prigione I, Basso G, Airoldi I.

Blood. 2010 Nov 11;116(19):3887-98. doi: 10.1182/blood-2009-10-248245. Epub 2010 Jul 29.

39.

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I.

Clin Cancer Res. 2010 Aug 15;16(16):4188-97. doi: 10.1158/1078-0432.CCR-10-0173. Epub 2010 Jun 29.

40.

The enigmatic role of interleukin-12 in the pathogenesis of Sjögren's syndrome: comment on the article by Vosters et al.

Airoldi I, Di Carlo E, Pistoia V.

Arthritis Rheum. 2010 Jul;62(7):2180; author reply 2180-1. doi: 10.1002/art.27484. No abstract available.

41.

Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies.

Pistoia V, Cocco C, Airoldi I.

J Clin Oncol. 2009 Oct 1;27(28):4809-16. doi: 10.1200/JCO.2008.21.3579. Epub 2009 Aug 31. Review.

PMID:
19720917
42.

IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.

Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G, Truini M, Grossi F, Galietta LJ, Ribatti D, Pistoia V.

PLoS One. 2009 Jul 1;4(7):e6119. doi: 10.1371/journal.pone.0006119.

43.

New perspectives for melanoma immunotherapy: role of IL-12.

Cocco C, Pistoia V, Airoldi I.

Curr Mol Med. 2009 May;9(4):459-69. Review.

PMID:
19519403
44.

Chemokines in neuroectodermal tumour progression and metastasis.

Raffaghello L, Cocco C, Corrias MV, Airoldi I, Pistoia V.

Semin Cancer Biol. 2009 Apr;19(2):97-102. doi: 10.1016/j.semcancer.2008.10.003. Epub 2008 Nov 1. Review.

PMID:
19013246
45.

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, Taverniti G, Di Carlo E, Cutrona G, Perfetti V, Rizzoli V, Ribatti D, Pistoia V.

Blood. 2008 Aug 1;112(3):750-9. doi: 10.1182/blood-2008-02-139378. Epub 2008 May 12.

46.

CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow.

Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V.

Cancer Immunol Immunother. 2008 Apr;57(4):541-8. Epub 2007 Sep 5.

PMID:
17786442
47.

Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.

Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, Watanabe M, Ribatti D, Pistoia V.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3996-4001. Epub 2007 Feb 23.

48.

Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.

Airoldi I, Cocco C, Di Carlo E, Disarò S, Ognio E, Basso G, Pistoia V.

Cancer Res. 2006 Apr 15;66(8):3978-80.

49.

CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications.

Airoldi I, Raffaghello L, Piovan E, Cocco C, Carlini B, Amadori A, Corrias MV, Pistoia V.

Clin Cancer Res. 2006 Jan 1;12(1):77-82.

50.

Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy.

Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M, D'Antuono T, Colombo MP, Pistoia V.

Blood. 2005 Dec 1;106(12):3846-53. Epub 2005 Aug 4. Erratum in: Blood. 2006 Jan 1;107(1):45. Colombo, Mario Paulo [corrected to Colombo, Mario Paolo].

Supplemental Content

Loading ...
Support Center